



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts**

Public declaration of interests

I, Giulio Pompilio

Organisation/Company: Centro Cardiologico Monzino IRCCS

Country: Italy

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

Period	Company	Category	Products	Therapeutic Indication
10/2012-08/2014	Nerviano Medical Sciences Group S.r.l	Executive role	Board of Directors	

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
04/2016-06/2016	Celyad	Cardiopoietic cells (C3BS-CQR-1)	Chronic advanced ischemic heart failure
02/2017-02/2018	Cook Regentec LLC	HemaTrate Blood Filtration System	Peripheral vascular disease
06/2017-12/2017	Cellprothera	StemXpand Cell Isolation System	Myocardial infarction

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

2

No interest declared

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
07/2011-12/2014	Miltenyi Biotec GmbH (Chairman, Safety Monitoring Board PERFECT Trial)	CD133 positive autologous bone marrow stem cells	coronary artery disease with indication for coronary artery bypass grafting

2.6 Investigator

Period	Company	Products	Therapeutic Indication
05/2015-10/2016	Mesoblast, Inc.	Bone marrow-derived Stro3 mesenchymal precursor cells (MPC)	ST-elevation myocardial infarction (AMICI Trial)

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Italfarmaco S.p.A.	Screening of a putative therapeutic drug Givinostat in IPS-derived cardiomyocytes from Duchenne and Becker muscular dystrophy patients

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

? Academic trials and publicly funded research/development initiatives involving pharmaceutical products:

- 1) Project PI: Phase I/II trial of NOGA-guided endocavitary injection of bone-marrow-derived CD133+ cells in ischemic refractory cardiomyopathy (RECARDIO trial) - Founded by the Italian Ministry of Health (Ricerca Finalizzata 2010)
- 2) Project PI: Studio randomizzato con placebo di mobilitazione di progenitori midollari con G-CSF in pazienti con disfunzione ventricolare successiva ad infarto miocardico anteriore esteso: STEM-AMI2 trial - Founded by the Lombardy Region (Ricerca Indipendente 2013)

? Scientific Director (2011-2016) of AriSLA Foundation, the Agency for Research on Amyotrophic Lateral Sclerosis (Italy).

? Nucleus Member (current) of the Working Group on Cardiovascular Regenerative and Reparative Medicine - European Society of Cardiology

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties,

Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	GIULIO POMPILIO
Date:	2020-02-21

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template